Raymond James Believes CareDx (CDNA) Still Has Room to Grow


Raymond James analyst John Hsu maintained a Buy rating on CareDx (CDNA) today and set a price target of $46. The company’s shares opened today at $38.90, close to its 52-week high of $39.38.

Hsu has an average return of 45.1% when recommending CareDx.

According to TipRanks.com, Hsu is ranked #803 out of 5265 analysts.

Currently, the analyst consensus on CareDx is a Strong Buy with an average price target of $36.25, representing a -6.8% downside. In a report issued on March 7, Piper Jaffray also reiterated a Buy rating on the stock with a $42 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $39.38 and a one-year low of $6.33. Currently, CareDx has an average volume of 800.5K.

Based on the recent corporate insider activity of 74 insiders, corporate insider sentiment is neutral on the stock. Earlier this month, George Bickerstaff, a Director at CDNA bought 32,980 shares for a total of $36,938.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CareDx, Inc. operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.